Monique Curran1, Dene Simpson, Caroline Perry. 1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
Abstract
UNLABELLED: Ertapenem, a carbapenem antibacterial, has in vitro activity against many Gram- negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria that are commonly associated with various infections.Once-daily parenteral (intravenous or intramuscular) ertapenem 1g was as effective as comparator antimicrobial agents (piperacillin/tazobactam or ceftriaxone +/- metronidazole) in patients with bacterial infections in randomised, double-blind, multicentre clinical trials. Response rates with ertapenem were 84% and 87% (combined microbiological and clinical) in patients with complicated intra-abdominal infections (CIAI), 82% (clinical) in patients with complicated skin and skin structure infections (CSSSI), 86% and 92% (microbiological) in patients with complicated urinary tract infections (CUTI), 92% (clinical) in patients with community-acquired pneumonia (CAP) associated with typical pathogens and 94% (clinical) in patients with acute pelvic infection. Respective response rates were statistically equivalent to those with comparators (81-94%). The efficacy of ertapenem was equivalent to that of piperacillin/tazobactam in patients infected with Enterobacteriaceae or anaerobes and to ceftriaxone in patients infected with Enterobacteriaceae. Ertapenem was generally well tolerated by patients with bacterial infections, with most adverse events being mild to moderate in severity. The most common ertapenem-associated adverse events were diarrhoea, infused vein complication, nausea, headache, vaginitis in females, phlebitis and/or thrombophlebitis and vomiting. CONCLUSION: Ertapenem is a broad-spectrum parenteral antibiotic with activity against many Gram-negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria and is suitable for once-daily administration. Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved.
UNLABELLED: Ertapenem, a carbapenem antibacterial, has in vitro activity against many Gram- negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria that are commonly associated with various infections.Once-daily parenteral (intravenous or intramuscular) ertapenem 1g was as effective as comparator antimicrobial agents (piperacillin/tazobactam or ceftriaxone +/- metronidazole) in patients with bacterial infections in randomised, double-blind, multicentre clinical trials. Response rates with ertapenem were 84% and 87% (combined microbiological and clinical) in patients with complicated intra-abdominal infections (CIAI), 82% (clinical) in patients with complicated skin and skin structure infections (CSSSI), 86% and 92% (microbiological) in patients with complicated urinary tract infections (CUTI), 92% (clinical) in patients with community-acquired pneumonia (CAP) associated with typical pathogens and 94% (clinical) in patients with acute pelvic infection. Respective response rates were statistically equivalent to those with comparators (81-94%). The efficacy of ertapenem was equivalent to that of piperacillin/tazobactam in patients infected with Enterobacteriaceae or anaerobes and to ceftriaxone in patients infected with Enterobacteriaceae. Ertapenem was generally well tolerated by patients with bacterial infections, with most adverse events being mild to moderate in severity. The most common ertapenem-associated adverse events were diarrhoea, infused vein complication, nausea, headache, vaginitis in females, phlebitis and/or thrombophlebitis and vomiting. CONCLUSION:Ertapenem is a broad-spectrum parenteral antibiotic with activity against many Gram-negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria and is suitable for once-daily administration. Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved.
Authors: Barbara A Pelak; Diane M Citron; Mary Motyl; Ellie J C Goldstein; Gail L Woods; Hedy Teppler Journal: J Antimicrob Chemother Date: 2002-11 Impact factor: 5.790
Authors: Donald G Musson; Anup Majumdar; Kimberly Birk; Sherry Holland; Peter Wickersham; Susan X Li; Goutam Mistry; Alison Fisher; Scott Waldman; Howard Greenberg; Paul Deutsch; J Douglas Rogers Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: Arturo S Dela Pena; Walter Asperger; Ferdinand Köckerling; Raul Raz; Reinhold Kafka; Brian Warren; Malathi Shivaprakash; France Vrijens; Hilde Giezek; Mark J DiNubile; Christina Y Chan Journal: J Gastrointest Surg Date: 2006-04 Impact factor: 3.452
Authors: Vicki L Collins; Dror Marchaim; Jason M Pogue; Judy Moshos; Suchitha Bheemreddy; Bharath Sunkara; Alex Shallal; Neelu Chugh; Sara Eiseler; Pragati Bhargava; Christopher Blunden; Paul R Lephart; Babar Irfan Memon; Kayoko Hayakawa; Odaliz Abreu-Lanfranco; Teena Chopra; L Silvia Munoz-Price; Yehuda Carmeli; Keith S Kaye Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191
Authors: Mathias W R Pletz; Mareike Rau; Juergen Bulitta; Andres De Roux; Olaf Burkhardt; Guido Kruse; Michael Kurowski; Carl E Nord; Hartmut Lode Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191
Authors: George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky Journal: Drugs Date: 2007 Impact factor: 9.546